Abzena is the leading end-to-end integrated CDMO for Antibody Drug Conjugates (ADCs) and complex biologic molecules with headquarters in San Diego, CA and additional centres of excellence in Bristol, PA and Cambridge, UK. Abzena has extensive experience in developing Biologics and Bioconjugates, and provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. Forward-thinking and committed, Abzena finds the best solutions and uses the right technologies to design, develop and manufacture products to ensure we get vital medicines to patients. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors and Biospring Partners.
Location: United Kingdom
Employees: 501-1000
Total raised: $75M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | Beringea | beringea.c... |
| - | Beringea | beringea.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.03.2022 | Private Eq... | $65M | - |
| 28.07.2020 | - | $10M | - |
Mentions in press and media 15
| Date | Title | Description | Source |
| 12.03.2024 | Antibody-Drug Conjugates: Next-Generation Linker Technology ... | www.abzena.com In this free webinar, gain insights into designing and developing a bioconjugate or a... | prweb.com/... |
| 12.04.2022 | Abzena commits chunk of new $65M investment to build out ... | A San Diego CDMO has landed a $65 million investment to expand its drug substance and fill-fi... | endpts.com... |
| 04.02.2022 | Lyell CSO: New job is 'the missing piece' of his career; Orp... | Gary Lee “I fully recognize that cell therapy is still all about the cells.” In moving over to his s... | endpts.com... |
| 28.01.2022 | Blueprint Medicines gets more ducks in a row before CEO ... | Philina Lee → When Jeff Albers announced he would no longer be CEO of Blueprint Medicines, the... | endpts.com... |
| 28.06.2021 | Early Therapeutic Antibody Development: Addressing the Chall... | Register for this webinar to hear a discussion about how the use of stage-appropriate tools can be e... | prweb.com/... |
| 24.06.2021 | Process Development: Getting from Phase I to III, Upcoming W... | In moving through the CMC development cycle, it is important to prospectively identify where there m... | prweb.com/... |
| 26.04.2021 | Addressing Immunogenicity Challenges to Select the Best Drug... | There has been a growing interest over the past decade in developing methods to assess the risk of u... | prweb.com/... |
| 15.04.2021 | Abzena picks North Carolina as the home for its 6th manu... | While Boston and San Francisco are the unquestioned leading biotech hubs in the US, drugmaker... | endpts.com... |
| 29.01.2021 | Oligonucleotide ADC Design and Development – An Emerging Fie... | As AOC therapeutic drug development grows, there is a need to for robust, reproducible, and well-def... | prweb.com/... |
| 12.01.2021 | Abzena plots 6th biologics plant as demand for mammalia... | With demand for biologics manufacturing at an all-time high, UK CDMO Abzena has rushed to a... | endpts.com... |
Show more